Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 28862


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Biotechnology
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28862

License Grant
The Inventors assign to the Company all of their right, title and interest in and to the invention and any related intellectual property owned by them.
License Property
This agreement is regarding certain intellectual property developed relating to uses of adenosine 5’-triphosphate (ATP) in combination with an antibiotic to eliminate tumor cells.

IPSCIO Record ID: 26866

License Grant
The Company acquired from Licensor, an individual, the exclusive rights to two issued United States patents and one patent application pending in the United States covering (i) the use of adenosine 5-diphosphate (ADP) and adenosine 5-triphosphate (ATP) to arrest and kill tumor cells (United States patent issued November 1989); (ii) the arrest of growth of tumor cells due to an increase in blood and plasma levels of ATP in a host resulting from the administration to the host of adenosine monophosphate (AMP) or ATP and a reduction in weight loss caused by cancer cachexia by administration of AMP or ATP (United States patent issued September 1991); and (iii) the utilization of adenosine nucleotides and/or adenosine and inorganic phosphates for elevation of liver, blood and blood plasma ATP concentrations (United States patent pending).
License Property
ATP – a sterile formulation of adenosine triphosphate – under development for the treatment of solid tumors or cancer-related cachexia.
Field of Use
The product has completed one single-center Phase I and one multicenter Phase II clinical trial, and the Company believes the results support the continued investigation of the drug as an adjunctive therapy that may improve the quality of life in patients suffering from non-small cell lung cancer.

IPSCIO Record ID: 6081

License Grant
The Inventors grant an exclusive, worldwide license to the Invention and any related intellectual property owned by them in the area of adenosine or ATP for use in infertility, including without limitation, U.S. Patent No. 5474890 and any subsequent United States or foreign patents issued based on the Invention and any subsequent improvements thereto made by the Inventors. The License includes the right to develop, make, have made, use, import, sell and offer for sale products based on the Invention Licensed Property and to sublicense third parties with respect to the foregoing.
License Property
Inventors are the sole owners of certain intellectual property developed by them relating to uses of adenosine 5’-triphosphate (ATP) in enhancing human sperm motility and fertilizing ability and in evaluating the fertilization potential of such sperm.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.